Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation StudyKhoan Vu, Weiyun Z. Ai, Erika Cavallone et al.|Clinical Cancer Research|2019Cited by 40
A Multicenter Phase I Dose-Finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin in Combination with Pegylated Liposomal Doxorubicin for the Treatment of Adults with Relapsed or Refractory Cutaneous and Peripheral T-Cell LymphomasWeiyun Z. Ai, Jonathan E. Brammer, Pierluigi Porcu et al.|Blood|2017Cited by 0